Montreal, 31 March 2020
Dear Colleagues,
The World Anti-Doping Agency (WADA) invites stakeholders to participate in a consultation process regarding the new Technical Letter TL22 - Ethylmorphine. This document includes guidance regarding the detection of the threshold substance morphine at a concentration higher than the Decision Limit in urine samples, which may result from the administration of the permitted drug ethylmorphine.
Stakeholders are invited to review this Technical Letter and provide comments by 10 April 2020, using WADA’s online consultation platform, WADAConnect.
Under the International Standard for Laboratories (ISL), WADA’s Technical Letters provide specific direction to WADA-accredited laboratories; WADA-approved laboratories for the Athlete Biological Passport; and, other stakeholders on particular issues regarding the analysis, interpretation and reporting of results for specific Prohibited Substance(s) and/or Prohibited Method(s) or on the application of specific laboratory procedures.
For any questions related to the above, we invite you to contact science@wada-ama.org.
We thank you in advance for your feedback.
Best regards,
World Anti-Doping Agency |
|